Merus (NL)

Merus discovers and develops innovative therapeutic antibodies with improved clinical efficacy based on its single light chain antibody technologies.

Single light chain (sLC) antibodies share a common immunoglobulin light chain while retaining the exquisite specificity and high affinity of antibodies with diversified light chains. Multiple sLC human antibodies against different epitopes/targets are efficiently co-expressed in a single manufacturing cell to generate novel antibody formats like full length IgG bispecific antibodies and mixtures of IgG antibodies. By combining multiple mechanisms of action, these formats provide the basis for enhanced disease-modifying targeted therapies.

Merus enjoys financial support from blue chip life science investors including Novartis Venture Funds, Pfizer Venture Investments, Aglaia Biomedical Ventures , Bay City Capital and LSP.